Back to Search
Start Over
Prophylactic effects of interleukin-2 receptor antagonists against graft-versus-host disease following unrelated donor peripheral blood stem cell transplantation.
- Source :
-
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation [Biol Blood Marrow Transplant] 2012 May; Vol. 18 (5), pp. 754-62. Date of Electronic Publication: 2011 Sep 29. - Publication Year :
- 2012
-
Abstract
- Basiliximab and daclizumab, two interleukin-2 receptor antagonists (IL-2RAs), prevent graft failure in renal transplantation, which also effectively treat steroid-refractory graft-versus-host disease (GVHD). However, only a few studies report that IL-2RAs prevent GVHD. Here we first retrospectively explored the prophylactic effects of basiliximab or daclizumab against GVHD in 82 patients with hematologic malignancies following unrelated donor-peripheral blood stem cell transplantation (URD-PBSCT). All recipients achieved engraftment. The rates of grade II-IV and III-IV acute GVHD (aGVHD) were 35.4% and 15.9%, respectively. Chronic GVHD (cGVHD) developed in 38.7% of evaluable patients. The transplantation-related mortality was 13.4%, while relapse rate was 8.5%. The 2-year overall survival (OS) reached 77.1% and disease-free survival (DFS) accumulated to 72.2%. The side effects of basiliximab and daclizumab were moderate and tolerable. There were no significant differences in aGVHD onset and survival between the daclizumab and basiliximab groups. However, basiliximab presented superior prophylactic effects on cGVHD than daclizumab. In conclusion, basiliximab or daclizumab prevents GVHD efficiently and feasibly following URD-PBSCT, and contributes to favorable outcome. Basiliximab has a similar effect on aGVHD but superior activity against cGVHD. Further prospective and randomized control studies are needed.<br /> (Copyright © 2012 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.)
- Subjects :
- Adolescent
Adult
Antibodies, Blocking administration & dosage
Antibodies, Blocking therapeutic use
Antibodies, Monoclonal administration & dosage
Antibodies, Monoclonal, Humanized administration & dosage
Basiliximab
Child
China
Daclizumab
Female
Humans
Immunoglobulin G administration & dosage
Leukemia, Lymphoid immunology
Leukemia, Lymphoid mortality
Male
Middle Aged
Neoplasm Grading
Receptors, Interleukin-2 immunology
Recombinant Fusion Proteins administration & dosage
Recurrence
Retrospective Studies
Survival Analysis
Unrelated Donors
Antibodies, Monoclonal therapeutic use
Antibodies, Monoclonal, Humanized therapeutic use
Graft vs Host Disease prevention & control
Immunoglobulin G therapeutic use
Leukemia, Lymphoid therapy
Peripheral Blood Stem Cell Transplantation
Receptors, Interleukin-2 antagonists & inhibitors
Recombinant Fusion Proteins therapeutic use
Subjects
Details
- Language :
- English
- ISSN :
- 1523-6536
- Volume :
- 18
- Issue :
- 5
- Database :
- MEDLINE
- Journal :
- Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
- Publication Type :
- Academic Journal
- Accession number :
- 21963619
- Full Text :
- https://doi.org/10.1016/j.bbmt.2011.09.005